Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study by Miller, David H et al.
RESEARCH ARTICLE
Brain atrophy and disability worsening in primary
progressive multiple sclerosis: insights from the INFORMS
study
David H. Miller1, Fred D. Lublin2, Maria Pia Sormani3, Ludwig Kappos4, €Ozg€ur Yaldizli5,
Mark S. Freedman6, Bruce A. C. Cree7, Howard L. Weiner8, Catherine Lubetzki9,
Hans-Peter Hartung10, Xavier Montalban11, Bernard M. J. Uitdehaag12, David G. MacManus1,
Tarek A. Yousry1, Claudia A. M. Gandini Wheeler-Kingshott1, Bingbing Li13, Norman Putzki14,
Martin Merschhemke14, Dieter A. H€aring14 & Jerry S. Wolinsky15
1Queen Square MS Centre, UCL Institute of Neurology, London, UK
2The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, New York
3Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore 1, Genoa 16132, Italy
4Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland
5Department of Neurology, University Hospital Basel, Basel, Switzerland
6The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario
7Multiple Sclerosis Center, University of California, San Francisco, California
8Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
9Center of Clinical Investigation, Salpe^triere Hospital APHP, University Paris 6, Paris, France
10Department of Neurology, Medical Faculty, Heinrich-Heine University, D€usseldorf, Germany
11Hospital Universitari Vall d’Hebron, Barcelona, Spain
12VU University Medical Center, Amsterdam, The Netherlands
13Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
14Novartis Pharma AG, Basel, Switzerland
15McGovern Medical School, UTHealth, Houston, Texas
Correspondence
David H. Miller, Queen Square MS Centre,
UCL Institute of Neurology, London, WC1N
3BG, UK.
Tel: +44 (0)20 3108 7425;
E-mail: david.h.miller@ucl.ac.uk
Funding Information
Novartis Pharma AG (Basel, Switzerland)
supported this study.
Received: 5 September 2017; Revised: 19
December 2017; Accepted: 22 December
2017
Annals of Clinical and Translational
Neurology 2018; 5(3): 346–356
doi: 10.1002/acn3.534
Abstract
Objective: To investigate the relationship between brain volume and disability
worsening over ≥3 years in the natural history of primary progressive multiple scle-
rosis using data from the placebo group of the INFORMS trial (n = 487; clinicaltri-
als.gov NCT00731692). Methods: Magnetic resonance imaging scans were
collected annually. Brain volume loss was determined using SIENA. Patients were
stratified by baseline normalized brain volume after adjusting for demographic
and disease-burden covariates. Results: Baseline normalized brain volume was
predictive of disability worsening: Risk of 3-month confirmed disability progres-
sion was reduced by 36% for high versus low baseline normalized brain volume
(Cox’s model hazard ratio 0.64, P = 0.0339; log-rank test: P = 0.0297). Moreover,
on-study brain volume loss was significantly associated with disability worsening
(P = 0.012) and was evident in patients with or without new lesions or relapses.
Brain volume loss depended significantly on baseline T2 lesion volume
(P < 0.0001). Despite low inflammatory activity at baseline (13% of patients had
gadolinium-enhancing lesions) and throughout the study (mean 0.5 new/enlarg-
ing T2 lesions and 172 mm3 T2 lesion volume increase per year), baseline T2
lesion volume was substantial (mean 10 cm3). Lower normalized brain volume at
baseline correlated with higher baseline T2 volume and older age (both
P < 0.0001). Interpretation: Baseline brain volume and the rate of ongoing brain
atrophy are significantly associated with disability worsening in primary progres-
sive multiple sclerosis. Brain volume loss is significantly related to baseline T2
lesion volume, but partially independent of new lesion activity, which might
explain the limited efficacy of anti-inflammatory treatment.
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Introduction
The INFORMS study evaluated the effect of fingolimod
0.5 mg versus placebo on disability progression in
patients with primary progressive multiple sclerosis
(PPMS) treated for at least 3 years.1 Patients recruited
to the INFORMS study had low inflammatory MRI
activity at baseline and on study, a low on-study
relapse rate, and a high on-study progression rate.
Despite the low level of inflammatory activity, approxi-
mately 80% of the INFORMS population experienced a
3-month confirmed disability progression. Although
fingolimod significantly reduced inflammatory activity
relative to placebo, the composite primary efficacy
endpoint of disability progression was not met, indi-
cating that fingolimod’s anti-inflammatory effects did
not slow disease worsening in PPMS. This observation
suggests that concurrent inflammatory disease activity
as measured by new lesion formation on brain MRI is
not the primary mechanism of disability progression in
PPMS.
Many studies in relapse-onset multiple sclerosis
(RMS) found a relationship between brain volume loss
and disability worsening.2–5 Moreover, patients with
RMS and a small normalized brain volume are signifi-
cantly more likely to worsen over 4 years than patients
with large normalized brain volume but otherwise simi-
lar baseline characteristics.6 Fingolimod reduced the risk
of disability worsening in relapsing-remitting MS
(RRMS) and consistently reduced brain volume loss by
more than 30% compared with placebo or interferon-
beta in three randomized, controlled clinical trials.7–9 In
PPMS, however, fingolimod treatment did not reduce
disability worsening or brain volume loss, perhaps sug-
gesting differences in pathogenesis of both disability pro-
gression and brain volume loss between RRMS and
PPMS.1 The question arises whether normalized brain
volume and brain volume loss are associated with dis-
ability progression in PPMS. An association between
brain volume loss and the clinical disease course would
support the value of brain volume loss as a surrogate
measure of disability progression in this clinical sub-
group.
The INFORMS placebo group provides a selected “nat-
ural history” population of PPMS patients with ≥3 years
of on-study assessment. The present analysis aimed to (1)
describe differences between untreated PPMS patients
with a stable, moderate, or severe clinical disease course
as measured by EDSS, (2) investigate the predictive value
of normalized brain volume for clinical decline in
untreated PPMS, and (3) investigate the relationship
between previous and concurrent inflammatory lesion
activity, brain volume loss, and clinical decline.
Methods
The INFORMS study
Key inclusion criteria for INFORMS were a clinical diag-
nosis of PPMS, disease duration 2–10 years, and objective
evidence of disability progression in the past 2 years.1 At
baseline, the placebo population (n = 487) had a median
age of 49 years, median of 5.7 years since onset of symp-
toms, median Expanded Disability Status Scale (EDSS)10
score of 4.5; and 13% of patients had gadolinium-enhan-
cing T1 (Gd+) lesions. Over the ≥3-year course of the
study, there was a mean of 0.5 new/enlarging T2 lesions
per patient per year, and 8% of patients experienced a
relapse.1 The study found no significant difference
between fingolimod 0.5 mg and placebo for the compos-
ite primary endpoint, 3-month confirmed disability pro-
gression according to worsening of any one of: EDSS, 25-
foot timed-walk test (25’TWT),11 or nine-hole peg test
(9-HPT).11,12 The study was carried out in accordance
with the International Conference on Harmonisation
Guidelines for Good Clinical Practice and the Declaration
of Helsinki.13,14 The protocol, patient information, and
consent forms were approved by the relevant institutional
review boards, and all patients gave written informed
consent.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) scans were collected
at baseline and annually thereafter and were analyzed at a
central facility (Queen Square MS Centre, University Col-
lege London Institute of Neurology, London, UK). The
analyses reported here used MRI data processed and pre-
sented in the original report of the trial.1 Lesions were
identified by visual review of scans by trained readers. T2
lesion volumes were measured on 2D proton density-
weighted fast/turbo spin echo images using a semiauto-
mated contouring tool within JIM image analysis soft-
ware. Normalized brain volume and percent brain volume
change were derived using SIENAX and SIENA methods,
respectively, applied to 2D T1-weighted images.15
Prespecified statistical analyses of
normalized brain volume and on-study
disability worsening
The following analyses were defined prior to the unblind-
ing of the INFORMS database. Results for the placebo
group are reported. The normalized brain volume at base-
line was analyzed in a multiple regression model with age,
gender, baseline T2 lesion volume, baseline EDSS, and
duration of MS since first symptoms as explanatory
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parameters, similar to a model previously used in RMS.6
The parameters tested were previously identified as signif-
icant predictors of brain volume in studies of patients
with RMS.5 The results of this statistical model were
incorporated into the model that was used to predict
brain volume in patients with PPMS:
Model-predicted volume ¼ a
þ b T2 lesion volume
þ c  EDSS
þ d  AGE
þ e PPMS durationþ f male sex
where a = model intercept; b = coefficient for baseline T2
volume; c = coefficient for EDSS; d = coefficient for age;
e = coefficient for duration of PPMS; and f = coefficient
for gender. Patients were categorized into low, expected,
and high strata according to the baseline distribution of
the residuals from the model fit (i.e., the difference
between the observed and the model-predicted normal-
ized brain volume): low, ≤1 standard deviation (SD);
high, ≥1 SD; expected, within 1 SD of the mean. The pre-
dictive value of this categorization of baseline normalized
brain volume for on-study disability worsening was then
tested in a Cox regression model and in a stratified log-
rank test.
Percentage brain volume loss was modeled in a prede-
fined random coefficient model based on all data (only
the placebo data are reported here). The predefined
model included treatment, baseline T2 volume, baseline
number of Gd+ lesions, baseline normalized brain vol-
ume, and geographical region as fixed effects. T2 lesion
volume and number of Gd+ lesions were included in this
model based on a previous model selection conducted in
three RRMS studies.5
Post hoc analysis of clinical outcomes by
severity of the disease course
Patients’ clinical disease course during the study was cat-
egorized according to the incidence of 3-month con-
firmed EDSS progression, defined as increase from
baseline EDSS score by 1 point in patients with baseline
EDSS score of ≤5.0, or by 0.5 points in patients with
baseline EDSS score of ≥5.5. The stable group had no
confirmed progressions over the course of the study, the
moderate group had one confirmed progression, and the
severe group had ≥2 confirmed progressions. As a 3-
month confirmed EDSS progression is by definition a
clinically meaningful disease worsening, grouping
patients by the number of 3-month confirmed EDSS
progressions experienced in a comparable timeframe (the
study duration), stratifies patients by severity of the
clinical disease course. Clinical and MRI outcomes were
then summarized over the course of the study for pla-
cebo patients with a stable, moderate, and severe disease
course.
Results
Baseline characteristics by severity of on-
study disability worsening in the placebo
group
Of the total 487 patients in the placebo group, 86, 154,
and 247 patients were classified as severe, moderate, and
stable, respectively, according to on-study EDSS disabil-
ity worsening. Several differences in baseline characteris-
tics were observed between the severe group compared
with the moderate and stable groups (Table 1). Baseline
Gd+ lesions were uncommon overall, with the greatest
frequency observed in the severe group. Moreover, the
severe group was on average slightly younger, with
shorter time since diagnosis, greater mean T2 lesion vol-
ume, and greater normalized brain volume than the other
groups. Men and women were equally represented in the
moderate and stable groups; however, there were more
men in the severe group. Median follow-up in severe,
moderate, and stable patients was 3.7, 3.2, and 3.0 years,
respectively.
Clinical and MRI outcomes by severity of on-
study disability worsening in the placebo
group
Change from baseline in each of the three elements of the
composite endpoint was directionally consistent with the
three categories of disability worsening: stable, moderate,
and severe (Fig. 1). Inflammatory activity manifested by
the number of new or enlarging T2 lesions was low in all
groups; the annual rate of new/enlarging T2 lesions
between baseline and Month 36 was 0.79, 0.44, and 0.44
in the severe, moderate, and stable groups, respectively.
Low inflammatory activity was also reflected in the T2
lesion volume change; in the overall placebo group, the
mean change in T2 lesion volume was 127 mm3 in the
first year (median 0 mm3), and 172 mm3 per year over
3 years (median 14 mm3).
The mean brain volume change from baseline in the
placebo group was 0.55% (SD 0.665) to Year 1,
1.04% (1.017) to Year 2, and 1.50% (1.192) to
Year 3. The rate of brain volume loss was clearly dis-
tinct between severe, moderate, and stable patients
(Fig. 2). The difference was sustained even in the sub-
group of patients without evidence of on-study inflam-
matory activity, defined as the absence of relapses and
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the absence of new or enlarging T2 lesions during the
study (Fig. 2A). Over 3 years, among patients without
evidence of on-study inflammatory activity, mean loss
of brain volume was 1.65% (SD 1.26), 1.54%
(1.27), and 1.14% (0.87) in the severe, moderate,
and stable groups, respectively. These values translate to
a loss of 0.55%, 0.51%, and 0.38% per year respectively.
Patients with evidence of inflammatory activity during the
study lost numerically more brain volume than those with-
out (Fig. 2B); over 3 years mean loss of brain volume was
2.05% (1.67), 1.72% (1.30), and 1.34% (0.85) in the
severe, moderate, and stable groups, respectively. These val-
ues translate to a loss of 0.68%, 0.57%, and 0.45% per year,
respectively. Only in the subgroup with no on-study
inflammatory activity and no confirmed progressions (28%
of the placebo population) did the annualized rate of brain
volume loss (0.38%) approach the proposed cutoff that
separates pathologic from physiologic rates of brain volume
loss (0.37% per year).16 All the other disease course sub-
groups had higher rates of brain volume loss.
Correlates of baseline normalized brain
volume
In a prespecified analysis of the INFORMS study, base-
line correlates of low normalized brain volume were
investigated in the entire study population (before first
dose, irrespective of treatment allocation) using the same
multiple regression model and covariates previously used
in RMS (Table 2).6 The model explained 26% of the
total variability in normalized brain volume. Low nor-
malized brain volume at baseline was best correlated
with high baseline T2 volume and older age (both
P < 0.0001).
Baseline normalized brain volume as a
predictor of on-study disability worsening
in the placebo group
Baseline normalized brain volume adjusted for age, gen-
der, baseline T2 lesion volume, baseline EDSS, and dura-
tion of MS was predictive of disability worsening during
the study. Across all patients, there was a marginally sig-
nificant association between a low normalized brain vol-
ume and the risk of 3-month confirmed disability
progression based on the composite endpoint (Cox-
model, type-3 test, P = 0.0790; log-rank test, P = 0.0791).
Patients with a high baseline normalized brain volume
had a significantly lower risk of disability worsening than
patients with a low baseline normalized brain volume
(Cox’s model hazard ratio [high vs. low category]: 0.64,
P = 0.0339; log-rank test: P = 0.0297; Fig. 3 and Table 3).
A similar but nonsignificant trend was seen using the
EDSS-only endpoint instead of the composite endpoint
(data not shown).
Correlates of on-study brain volume loss in
the placebo group
On-study brain volume loss was significantly associated
with the risk of disability worsening across all patients
(P = 0.012; Fig. 4). Based on Month 24 scans, the greatest
brain volume loss quartile showed a 32% relative increase
in incidence of confirmed disability progression compared
with the lowest brain volume loss quartile (P = 0.0025;
Fig. 4). In a predefined random coefficient model, per-
centage brain volume loss depended strongly on baseline
T2 volume (P < 0.0001), but not on the other fixed effects
in the model (all other P values were nonsignificant).
Table 1. Demographics and baseline characteristics of the INFORMS placebo population by severity of on-study disability worsening.
Severe (N = 86) Moderate (N = 154) Stable (N = 247) Total (N = 487)
Age, years 46 (31–65) 49 (27–65) 49 (28–65) 49 (27–65)
Female, n (%) 35 (41) 77 (50) 123 (50) 235 (48)
Duration of MS since first symptom, years 5.5 (2–10) 6.1 (2–12) 5.5 (2–15) 5.7 (2–15)
Time since diagnosis, years 1.8 (0.1–7.9) 2.9 (0.2–9.3) 2.3 (0.1–10.4) 2.4 (0.1–10.4)
EDSS
Median (range) 4.5 (3–6) 5.5 (2–7) 4.0 (2–7) 4.5 (2–7)
Mean (SD) 4.6 (0.9) 4.9 (1.1) 4.5 (1.0) 4.7 (1.0)
Patients with Gd+ lesions, n/N (%) 18/86 (21) 18/152 (12) 25/246 (10) 61/484 (13)
Number of Gd+ lesions per patient, mean (SD) 0.45 (1.11) 0.24 (0.77) 0.24 (1.13) 0.28 (1.03)
Total volume of T2 lesions, cm3
Median (range) 5.4 (0.2–80.0) 6.3 (0.1–87.6) 5.0 (<0.1–92.0) 5.3 (<0.1–92.0)
Mean (SD) 11.2 (14.8) 10.5 (11.8) 9.4 (13.1) 10.0 (13.0)
Normalized brain volume, cm3 1508 (1282–1697) 1486 (1285–1664) 1503 (1206–1725) 1498 (1206–1725)
All values are median (range) unless otherwise stated; N, number in assessment group; n, number with characteristic; EDSS, expanded disability
status scale; SD, standard deviation; Gd+, gadolinium-enhancing T1; MS, multiple sclerosis; PPMS, primary progressive MS.
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Figure 1. Change from baseline in clinical outcomes by severity of on-study disability worsening in the placebo population. (A) EDSS, (B) 25’TWT,
(C) 9-HPT.
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The effect of baseline T2 lesion volume on brain volume
loss in the subgroup that was free of baseline Gd+ lesions is
illustrated in Figure 5A. The annualized rate of brain vol-
ume loss was 0.27%, 0.40%, 0.43%, and 0.70% in the <0.8,
0.8–<3.5, 3.5–12, and >12 cm3 baseline T2 lesion volume
groups, respectively. A similar pattern was observed using
baseline T2 volume quartiles (data not shown).
Rate of brain volume loss also tended to increase with
the number of Gd+ lesions at baseline, although this was
not statistically significant (P = 0.145; Fig. 5B), perhaps
due to the small number of patients with Gd+ lesions at
baseline. The annualized rate of brain volume loss was
0.47%, 0.63%, 0.70%, and 1.33% in the 0, 1, 2–3, and ≥4
baseline Gd+ lesion groups, respectively.
Discussion
Patients in the INFORMS trial exhibited very low levels
of inflammatory activity at baseline and throughout the
trial. Low inflammatory MRI activity together with the
observed low relapse rate is consistent with the currently
accepted definition of PPMS.17–19 Despite the low level of
inflammatory activity at the time of inclusion and there-
after, patients had a substantial T2 lesion volume at base-
line, indicating previous inflammatory activity, and a high
progression rate on-study, with accelerated brain volume
loss. The clinical disease course was well reflected in the
rate of brain volume loss, which was most rapid in the
severe subgroup who experienced ≥2 confirmed progres-
sions and least rapid in the stable subgroup who experi-
enced no confirmed progressions. These results confirm a
relationship between brain volume loss and disability
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Figure 2. Percentage brain volume change from baseline by severity of on-study disability worsening in the placebo population in patients (A)
without* and (B) with evidence of inflammatory activity during the study. *Defined as the absence of relapses and the absence of new or
enlarging T2 lesions during the study.
Table 2. Baseline normalized brain volume as a function of age, gen-
der, and baseline MS disease characteristics.
Predictor Coefficienta t-value P-value
Demographics
Age, per year 3.65 11.8 <0.0001
Male sex 11.26 2.16 0.030
Baseline disease characteristics
T2 volumeb 37.79 11.9 <0.0001
EDSS 2.75 1.1 0.281
Duration of MSc 0.586 0.18 0.856
Entire modeld SDresiduals 73 cm
3 Intercept 1742 cm3 <0.0001
This analysis was prespecified before database lock and includes the
entire study population (before first dose, irrespective of treatment
allocation) using the same multiple regression model and covariates
previously used in RMS.6 SD, standard deviation.
aCoefficient, predicted change in normalized brain volume (in cm3)
per unit change in the given predictor when all other predictors are
kept constant.
bTertiles: <2.8, 2.8–9.6, >9.6 cm3.
cTertiles: <4.52, 4.52–6.83, >6.83 years.
dUnadjusted r2 of the entire model: 26.4%.
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Figure 3. Predictive value of baseline normalized brain volume for on-study disability worsening in the placebo population. Kaplan–Meier curves
of low, expected, and high baseline normalized brain volume for cumulative probability of 3-month confirmed disability progression over 4 years
(composite endpoint). Normalized brain volume was predicted according to the covariates described in Table 2:
NBV = 1741.8  [37.79 9 t2v]  [3.65 9 age in years] + [11.26 if male]  [2.75 9 EDSS]  [0.586 9 PPMS], where t2v = 0 if the baseline T2
volume was <2825 mm3, t2v = 1 if the baseline T2 volume was between 2825 and 9599 mm3, and t2v = 2 if the baseline T2 volume was
>9599 mm3; PPMS = 0 if the duration of MS since first symptoms was <4.52 years, PPMS = 1 if duration was between 4.52 and 6.83 years, and
PPMS = 2 if duration was >6.83 years. The SD was 73.4 cm3. Patients were categorized into “low,” “expected,” and “high” strata according to
the baseline distribution of the residuals from this regression model fit (i.e., the difference between the observed and the model-predicted
normalized brain volume): low, ≤1 SD; high, ≥1 SD; expected, within 1 SD of the mean. Risk reduction high versus low normalized brain
volume: 36%, P = 0.0339, hazard ratio (HR) with 95% confidence interval (CI) 0.64 [0.42; 0.97], log-rank test: P = 0.0297. Risk reduction
expected versus low normalized brain volume: 24%, P = 0.0647, HR with 95% CI 0.76 [0.56; 1.02], log-rank test: P = 0.0612. Cox-model, type-
3 test of a general association: P = 0.0790; log-rank test, P = 0.0791. CDP, confirmed disability progression; NBV, normalized brain volume.
Table 3. Three-month confirmed disability progression (composite endpoint) by baseline normalized brain volume category.
Baseline normalized brain
volume category
Incidence of disability progression
over 3 years, %a (95% CI)
Risk of disability progression compared with low normalized
brain volume categoryb
Risk reduction, % HR (95% CI) P
Low (n = 70) 90.8 (82.9; 98.7)
Expected (n = 351) 73.8 (68.9; 78.8) 24.30 0.76 (0.56; 1.02) 0.0647
High (n = 61) 66.7 (53.8; 79.5) 36.47 0.64 (0.42; 0.97) 0.0339
aKaplan–Meier estimate.
bCox model.
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worsening in PPMS, consistent with findings in RMS.2–5
The relationship between brain volume loss and disability
worsening was sustained even in the absence of on-study
inflammatory activity, defined as new or enlarging T2
lesions or relapses. These results suggest that a notable
component of brain volume loss and disease worsening in
PPMS is independent of concurrent inflammatory
activity.
Baseline normalized brain volume and on-study brain
volume loss were both strongly dependent on the baseline
T2 lesion volume, consistent with previous findings from
three RRMS studies in the fingolimod program.5 Likewise
consistent with findings from RRMS,6 a small normalized
brain volume at baseline—in relation to the patient’s age,
gender, and MS disease characteristics—was a significant
predictor of on-study disease worsening over 3 years. The
results suggest that brain atrophy and on-study disability
progression in PPMS patients in INFORMS were to some
extent explained by lesion activity which had occurred
prior to study entry.
A key feature of this study is the insight it provides
into the natural history of PPMS based on a large placebo
cohort, albeit in a selected population from a randomized
controlled trial. Fingolimod did not slow disability wors-
ening in INFORMS, but it did significantly reduce inflam-
matory activity by 73% for number of new or newly
enlarging T2 lesions and by 78% for number of Gd+
lesions, as previously reported.1 Because the benefit/risk
of fingolimod in the INFORMS study did not support the
development of fingolimod in PPMS, we see no need to
further explore its effects. However, a post hoc pooled
analysis on the entire INFORMS dataset (fingolimod and
placebo) showed essentially similar results as reported
here for on-study brain volume loss and disability
worsening.20
The baseline T2 volume in the placebo group of
INFORMS (mean 10.0 cm3; median 5.3 cm3)1 was in the
range of that reported in other large PPMS trials (mean
10.9 cm3; median 6.2 cm3 in ORATORIO and mean
8.8 cm3; median 5.2 cm3 in OLYMPUS).21,22 The sub-
stantial baseline T2 lesion volume may be contrasted with
the low observed on-study activity. In the placebo popu-
lation of INFORMS, the mean increase in T2 lesion vol-
ume was 172 mm3 per year (median 14 mm3). At this
mean rate of lesion load increase, assuming a linear accu-
mulation rate at the population level, it would require
58 years to arrive at the observed mean baseline T2 lesion
volume; yet the median onset of MS from first symptoms
was only 5.7 years. A similar disparity was evident in the
ORATORIO trial.21 There is an apparent quantitative dis-
connect in many patients with PPMS between the low
rate of T2 volume increase observed on study, and the
substantial T2 lesion volume already present at study
entry. One possible explanation could be periods of
asymptomatic inflammation at younger age, before clini-
cal onset and diagnosis. Direct evolution from a radiolog-
ically isolated syndrome to symptomatic PPMS has been
recently reported.23 Consistent with the concept of an
earlier, more inflammatory disease phase, we found that
the proportion of patients with active lesions is greatest
in the youngest PPMS patients and decreases gradually
with older age, a pattern that is well known from RMS.24
A phase of higher but asymptomatic lesion activity would
also explain why PPMS patients have a higher average age
at diagnosis than RRMS patients. A higher level of
inflammation followed by a decline is consistent with the
observation that inflammatory activity declines over the
course of PPMS after diagnosis.25 Another possible con-
tributory factor in the disconnect between T2 volume and
on-study inflammatory activity could be a “regression to
the mean” during the study from a previous well-docu-
mented phase of active progression, mandated by the
inclusion criteria, during which subclinical inflammatory
activity may also have been above average. Additionally,
the disparity might be increased if the T2 volume includes
some lesions of ischemic origin rather than demyelinating
lesions due to MS.
In a predefined analysis, we identified baseline T2
lesion volume as the best predictor of on-study brain vol-
ume loss in the INFORMS trial among the set of tested
variables. Only the subgroup with a small baseline T2
lesion volume who were free of baseline Gd+ lesions
exhibited brain volume loss below a recently proposed
cutoff separating pathologic from physiologic rates of
brain volume loss (0.37% per year).16 Brain volume loss
increased gradually in patients who were categorized by
increasing baseline T2 lesion volume. This relationship
was sustained in patients who were free of Gd+ lesions at
baseline.
The risk of disability progression in INFORMS was
numerically greater in the subgroup of patients with Gd+
lesions at baseline (13%) than in patients without Gd+
lesions at baseline.24 Likewise, the treatment effect of fin-
golimod was numerically but not statistically significantly
stronger in the subgroup with baseline Gd+ lesions than
in the subgroup without baseline Gd+ lesions.24 Similar
results for disability progression and a dependence of the
treatment effect on the presence of Gd+ lesions were seen
in the OLYMPUS and ORATORIO trials.21,22
A mechanism that could link lesion load with ongoing
brain volume loss would be continued axonal loss within
longstanding white matter lesions, for example, due to
effects of low-grade intrinsic CNS inflammation, mito-
chondrial dysfunction, and energy failure in demyelinated
axons.26 However, there may also be pathological factors
other than white matter lesion load that contribute to
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ongoing brain volume loss (and disability progression) in
PPMS. Meningeal inflammation, cortical demyelination
and neurodegeneration,27 and inflammation and axonal
loss in the normal appearing white matter28 have all been
reported in PPMS. Resolution of an earlier phase of
inflammation-derived edema might also contribute to
brain volume loss.25,29
The analyses of brain volume loss reported here for the
placebo group of the INFORMS study might be useful for
the design of future Phase 2 trials of neuroprotective
agents in PPMS. Brain volume loss has potential as a pri-
mary endpoint in such studies. Based on the brain vol-
ume loss and the standard deviation observed in placebo
patients from INFORMS, and assuming a 40% relative
treatment effect, a total sample size of 280 patients (i.e.,
140 per arm using a parallel-group, placebo-controlled
design) would be required for a 1-year trial, or 188
patients (94 per arm) for a 2-year trial with brain volume
loss as the primary endpoint.
Overall, the results of INFORMS suggest that brain vol-
ume loss in PPMS is an important predictor and surro-
gate of clinical worsening. The T2 lesion burden at study
entry is one factor that can be clearly linked to the rate of
on-study brain volume loss and disease progression, while
new inflammatory activity seems to play a relatively
minor role.
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